Abilify MyCite

PreclinicalSmall molecule

Otsuka

Abilify MyCite is one of 9 small molecule programs targeting Medication. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

MedicationCompleted

MedicationPreclinical

Completed

Competition

Competitive Landscape

12 competitors in Medication

#DrugCompanyPhaseTrials

Ozempic

Novo Nordisk

Approved

1 2

Advil

KKenvue Brands

Approved

2 3

Methylphenidate /kg

FFlorida International University

Phase 3

1 4

Vyvanse

Takeda

Preclinical

1 5

Tianeptine

Pfizer

Preclinical

1 6

Biodentine

IIstanbul University

Preclinical

1 7

Glycyrrhizin

MMansoura University

Preclinical

1 8

Antiretroviral Drugs

NNational Institute of Allergy and Infectious Diseases (NIAID)

Preclinical

1 9

Abilify MyCite

Otsuka

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Medication1 trial

A Trial to Assess a Wearable Patch's Functioning to Detect Medication Ingestion

Completed· Otsuka logo

Otsuka·N/A·NCT06372210·54 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Abilify MyCite. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Abilify MyCite compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Abilify MyCite. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Otsuka company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: Otsuka

Abilify MyCite

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Medication1 trial

References

Drug Info

Quick Facts

Related News